Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
暂无分享,去创建一个
Afsaneh Barzi | Katrina Pedersen | Jeannine S McCune | Fang-Shu Ou | J. Sloan | B. Pasche | M. Lacouture | A. Barzi | H. Lenz | A. Grothey | T. Bekaii-Saab | F. Ou | E. Chiorean | T. Dockter | J. McCune | K. Ciombor | J. Meyers | Heinz-Josef Lenz | Axel Grothey | Daniel H Ahn | Kristen K Ciombor | Mario E Lacouture | E Gabriela Chiorean | James M Cleary | Tanios S Bekaii-Saab | Patrick M Boland | Erica N Heying | Travis J Dockter | Nisha L Jacobs | Boris C Pasche | Jeffrey P Meyers | Rodwige J Desnoyers | Jeffrey Sloan | D. Ahn | K. Pedersen | J. Cleary | P. Boland | R. Desnoyers | Erica N. Heying | N. Jacobs | Travis Dockter | Jeannine S. McCune | Jeff A. Sloan
[1] Y. Doki,et al. Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer that progressed after standard chemotherapy. , 2018 .
[2] Ying Cheng,et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2015, The Lancet. Oncology.
[3] Thomas J. Smith,et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[5] D. Sargent,et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[6] J. Blay,et al. Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. , 2014, The oncologist.
[7] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[8] W. Scheithauer,et al. Real-world dosing of regorafenib in metastatic colorectal cancer (mCRC): Interim analysis from the prospective, observational CORRELATE study. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] A W REID,et al. The use of cocoa syrups for masking the taste of quinine hydrochloride. , 1956, Journal of the American Pharmaceutical Association. American Pharmaceutical Association.
[10] Jianmin Pan,et al. Phase II clinical trials: issues and practices , 2014 .
[11] S. Erickson,et al. The Concordance of Self-Report With Other Measures of Medication Adherence: A Summary of the Literature , 2004, Medical care.
[12] D. Zopf,et al. Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity , 2011, International journal of cancer.
[13] D. Bangsberg. Monitoring Adherence to HIV Antiretroviral Therapy in Routine Clinical Practice: The Past, the Present, and the Future , 2006, AIDS and Behavior.
[14] Bradley C Martin,et al. Concordance among three self-reported measures of medication adherence and pharmacy refill records. , 2005, Journal of the American Pharmacists Association : JAPhA.
[15] F. Dalenc,et al. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. , 2011, The oncologist.
[16] T. Rummans,et al. Quality of life in hospice patients. A pilot study. , 1999, Psychosomatics.
[17] D. Sargent,et al. Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study. , 2013 .
[18] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.
[19] Lizheng Shi,et al. Concordance of Adherence Measurement Using Self-Reported Adherence Questionnaires and Medication Monitoring Devices , 2012, PharmacoEconomics.
[20] C. Cleeland,et al. The rapid assessment of fatigue severity in cancer patients , 1999, Cancer.
[21] V. Lee,et al. The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong , 2016, Postgraduate Medical Journal.